Salvensis

Salvensis is a UK-based biotechnology company dedicated to the discovery and development of new medicines for rare diseases and neglected tropical diseases (NTDs). Founded in 2017 by a team of experienced drug discovery scientists formerly with GSK, the company leverages its expertise in medicinal chemistry and biology to address significant unmet medical needs. Their portfolio includes programs targeting conditions such as malaria, leishmaniasis, and various rare genetic disorders. Salvensis operates through a collaborative model, partnering with academic institutions and non-profit organizations like the Medicines for Malaria Venture (MMV) to advance its pipeline. The company aims to bridge the gap between early-stage research and clinical development for diseases that are often overlooked by larger pharmaceutical firms.